Time to treatment discontinuation of second-line fulvestrant monotherapy for HR+/HER2-metastatic breast cancer in the real-world setting
Diamond, JR, JR; Potter, D; Salkeni, M; Silverman, P; Haddad, T; Forget, F; Awada, A; Canon, JL; Luhn, P; O'Hear, C; Ton, TG; Sanglier, T; Hsieh, R; Oliveri, E; Chuo, J; Xiao, Y; Emens, L
| HERO ID | 6322439 |
|---|---|
| In Press | No |
| Year | 2019 |
| Title | Time to treatment discontinuation of second-line fulvestrant monotherapy for HR+/HER2-metastatic breast cancer in the real-world setting |
| Authors | Diamond, JR, JR; Potter, D; Salkeni, M; Silverman, P; Haddad, T; Forget, F; Awada, A; Canon, JL; Luhn, P; O'Hear, C; Ton, TG; Sanglier, T; Hsieh, R; Oliveri, E; Chuo, J; Xiao, Y; Emens, L |
| Journal | Cancer Research |
| Volume | 79 |
| Issue | 4 |
| Page Numbers | P4-13-08-P4-13-08 |
| Doi | 10.1158/1538-7445.SABCS18-P4-13-08 |
| Wosid | WOS:000478677001420 |
| Url | https://aacrjournals.org/cancerres/article/79/4_Supplement/P4-13-08/639727/Abstract-P4-13-08-Time-to-treatment |
| Is Certified Translation | No |
| Dupe Override | No |
| Is Public | Yes |